Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Cash flows from operating activities:
Net loss	$ (18,627,887)	$ (18,816,628)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	295,859	277,178
Amortization	46,175	20,140
Other noncash items	5,724	0
Change in fair value of conversion option liability	(503,000)	0
Change in fair value of warrants liabilities	(731,000)	0
Amortization of right-of-use assets	508,422	574,682
Loss on fixed asset dispositions	62,650	676
Share-based compensation expense	790,145	444,147
Amortization of debt issuance costs and discount	1,387,050	1,192,574
Accretion of paid-in-kind interest	132,140	0
Changes in operating assets and liabilities:
Accounts receivable	(128,227)	(389,467)
Inventory	(2,693,926)	(2,379,205)
Prepaid and other assets	496,902	(139,136)
Accounts payable	334,829	207,481
Accrued expenses	474,724	6,753
Lease liabilities	(517,967)	(406,636)
Other liabilities	(23,178)	(36,568)
Net cash used in operating activities	(18,690,565)	(19,444,009)
Cash flows from investing activities:
Acquisition of patents	(105,091)	(86,058)
Purchases of property and equipment	(525,007)	(761,706)
Net cash used in investing activities	(630,098)	(847,764)
Cash flows from financing activities:
Proceeds from exercise of pre-funded warrants	500	0
Proceeds from exercise of common warrants	3,318,879	0
Proceeds from November 2025 convertible notes	12,000,000	0
Issuance costs for November 2025 convertible notes	(718,528)	0
Proceeds from common stock issued through ESPP	90,332	63,106
Proceeds from at-the-market sales of common stock	7,013,162	2,025,104
Issuance costs for at-the-market sales of common stock	(210,395)	(60,753)
Repayment of November 2023 convertible notes, including related parties	(6,765,000)	0
Repayment of note payable	(367,450)	0
Net cash provided by financing activities	25,135,255	2,027,457
Net change in cash and cash equivalents	5,814,592	(18,264,316)
Cash and cash equivalents:
Beginning of period	3,451,761	21,716,077
End of period	9,266,353	3,451,761
Cash paid for:
Interest	8,615	111,000
Income taxes	6,806	5,708
Non-cash investing and financing activities:
Property and equipment costs included in accounts payable and accrued expense	60,447	73,740
Acquisition of patents included in accounts payable	15,804	0
Conversion of November 2023 convertible notes into common stock	85,000	0
Payment of November 2023 convertible note interest in common stock	360,000	300,000
Deferred offering costs reclassified to additional paid-in-capital	15,637	3,143
Fair value of conversion option liability at November 2025 issuance	2,517,000	0
Fair value of warrants liabilities at November 2025 issuance	5,674,000	0
June 2025 Financing [Member]
Cash flows from financing activities:
Proceeds from the issuance of common stock	4,510,001	0
Issuance costs	(804,940)	0
Non-cash investing and financing activities:
Issuance of warrants for underwriter commission	56,035	0
August 2025 Financing [Member]
Cash flows from financing activities:
Proceeds from the issuance of common stock	7,998,826	0
Issuance costs	(930,132)	0
Non-cash investing and financing activities:
Issuance of warrants for underwriter commission	$ 97,612	$ 0